Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases

Launched by PARDIS NOOR MEDICAL IMAGING AND CANCER CENTER · Mar 13, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for patients with liver metastases, which is when cancer spreads to the liver from other parts of the body. The trial combines a procedure called Transarterial Chemoembolization (TACE) with a drug called Bevacizumab. TACE delivers chemotherapy directly to the tumor, which can help reduce side effects and increase the effectiveness of the treatment. Bevacizumab is designed to prevent the growth of new blood vessels that tumors need to grow. By combining these two methods, researchers hope to see if this approach can improve survival and effectiveness for patients with liver metastases.

To be eligible for the study, participants should have confirmed metastatic liver cancer and meet certain health criteria, such as having good liver function and a stable overall health status. The trial is open to adults aged 18 and older who have not had prior liver surgery or specific previous treatments. Participants can expect to receive the combined treatment and will be monitored closely for their health and response to the therapy. This trial is currently not recruiting participants yet, but it aims to provide valuable insights into a potentially promising treatment for those with advanced liver cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Confirmation of metastatic liver cancer via histological examination or a characteristic imaging profile on dynamic computed tomography (CT) scan or magnetic resonance imaging (MRI) without indications for surgical resection
• • Eastern cooperative oncology group performance status (ECOGPS) of 0 or 1
• • Liver function categorized as Child-Pugh class A or B
• • Stable non-hepatic metastases, such as skeletal, pulmonary, or lymph node metastases
• • Hepatic tumor burden below 70%
• • Expected survival duration exceeding six months
• • Laboratory findings meeting specific criteria, including platelet count \>50×109 /L, hemoglobin \>8.0 g/dL, ANC count ≥1.5 × 109/L, bilirubin \<51 mmol/L, alanine and aspartate aminotransferase \<3 times the upper limit of the normal range, and serum creatinine \<1.5 times the upper limit of the normal range.
• Exclusion Criteria:
• • Active infection
• • Presence of severe comorbidities, such as hepatic encephalopathy, refractory ascites, and esophageal variceal bleeding
• • Prior liver resection
• • Previous TACE therapy received at other healthcare facilities
• • Poor performance status (ECOGPS \> 1)